The Role of Steroids Following Selective Laser Trabeculoplasty - Full Text View

Sponsored by:	West Virginia University
Information provided by:	West Virginia University
ClinicalTrials.gov Identifier:	NCT00406042

Purpose

To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.

Condition	Intervention
Glaucoma	Drug: prednisolone acetate 1%

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Prednisolone 6-Methylprednisolone Depo-medrol Medrol veriderm Methylprednisolone Methylprednisolone hemisuccinate Methylprednisolone Sodium Succinate Prednisolone acetate Prednisolone sodium phosphate Prednisolone Sodium Succinate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty

Further study details as provided by West Virginia University:

Primary Outcome Measures:

Intraocular pressure reduction

Secondary Outcome Measures:

Anterior chamber inflammation

Estimated Enrollment:	25
Study Start Date:	September 2005
Study Completion Date:	June 2006

Detailed Description:

Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

glaucoma or ocular hypertension
need for bilateral SLT

Exclusion Criteria:

eye disease precluding accurate IOP measurement
contraindication to topical prednisolone acetate

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406042

Locations

United States, West Virginia
West Virginia University Eye Institute
Morgantown, West Virginia, United States, 26505

Sponsors and Collaborators

West Virginia University

Investigators

Principal Investigator:

Tony Realini, MD

West Virginia University Eye Institute

More Information

Study ID Numbers:	16678
Study First Received:	November 29, 2006
Last Updated:	March 28, 2007
ClinicalTrials.gov Identifier:	NCT00406042
Health Authority:	United States: Institutional Review Board

Keywords provided by West Virginia University:

glaucoma
trabeculoplasty
steroids

Study placed in the following topic categories:

Methylprednisolone
Glaucoma
Eye Diseases
Prednisolone
Methylprednisolone acetate

Prednisolone acetate
Methylprednisolone Hemisuccinate
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Protective Agents

Neuroprotective Agents
Glucocorticoids
Hormones
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009